Results 151 to 160 of about 14,136,043 (289)

Failure in Motion: A Framework for Capability Erosion and Institutional Dysfunction

Strategic Change, EarlyView.
ABSTRACT Drawing on the literature on capability erosion and institutional dysfunction (ID), this study develops a conceptual framework that sheds new light on how the interaction between capability erosion and ID creates conditions for business failure across borders. By articulating two dimensions of heterogeneous capability and resource erosion (i.e.
Joseph Amankwah‐Amoah, Ahmed Adel Tantawy   +1 more
wiley   +1 more source

Cross-Cultural Validation of Manual and Automated Methods for Extracting Trauma Memory Features and Predicting PTSD in Young Populations. [PDF]

Res Child Adolesc Psychopathol
Giuliani A, Sharp T, Chideya Y, Spurgin K, Meiser-Stedman R, Tomlinson M, Halligan SL.   +6 more
europepmc   +1 more source

Ultrasound‐Guided Liposomal vs. Conventional Bupivacaine Erector Spinae Plane Block Plus Gabapentin for Postherpetic Neuralgia

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to compare efficacy and safety of ultrasound‐guided erector spinae plane block (ESPB) using liposomal (LB) versus conventional bupivacaine (CB), each plus standardized gabapentin, in patients with postherpetic neuralgia (PHN). A total of 116 PHN patients were randomized to ESPB‐LB or ESPB‐CB; both groups received standardized ...
Xia‐Jing Xu, Li‐Juan Liu, Fa‐Ming Xu, Xiang‐Yu Fang   +3 more
wiley   +1 more source

Through the Cultural Prism: The Influence of a Distinctive Chinese Personality-Junzi Personality-On Psychosocial Adjustment in China. [PDF]

Int J Psychol
Zhao B, Liu C, Muhetaer P, Hu P.
europepmc   +1 more source

Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch, Athena Mancini, Adham Elsherbini, Jason Yuen, Andres Lozano   +4 more
wiley   +1 more source

Geschäftsbericht ...

, 2012
Bilfinger-Berger SE
core  

Are Academic Executives Greener? Evidence From China

Managerial and Decision Economics, EarlyView.
ABSTRACT This paper investigates the impact of executives with academic backgrounds (“academic executives”) on corporate green patents. We find that both the presence of academic executives and the proportion of academic executives have a significantly positive impact on firms' green patents, and this effect is positively associated with the firm's ...
Kai Xing, Xiong Li, Ping Liu, Hanxiong Zhang, Yuhan Xiao   +4 more
wiley   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Eco-Friendly Selenium-Hyaluronic Acid Nanoconjugates with Potent Anticancer, Antimicrobial, Anti-Inflammatory and Wound-Healing Activities. [PDF]

Polymers (Basel)
Qanash H, Alharbi B, Bazaid AS, Alsaif G, Alharazi T, Binsaleh NK.   +5 more
europepmc   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source